Atlas One · Human · Molecular

ATP (Adenosine Triphosphate)

The universal energy currency — a 507 Da purine nucleotide whose γ-phosphate bond hydrolysis (~30–65 kJ/mol) couples catabolism to every energy-demanding process in biology: muscle contraction, active transport, biosynthesis, and signal transduction.

The human body synthesizes and recycles approximately 40 kg of ATP per day through continuous mitochondrial oxidative phosphorylation driven by the proton-motive force. Fritz Lipmann identified ATP as the central “phosphate bond energy” carrier in 1941; Paul Boyer’s rotational mechanism for F₀F₁-ATP synthase earned the 1997 Nobel Prize in Chemistry. In the heart, ATP depletion during ischemia impairs Ca²⁺ cycling within seconds and underlies the cascade from vascular occlusion to infarction.

507 DaMolecular weight
~40 kgRecycled / day
CHEBI:15422ChEBI ID
~30.5 kJ/molΔG hydrolysis (standard)
Atlas One · Molecular · Nucleotide / Universal Energy Carrier

ATP (Adenosine Triphosphate)

Class: Purine nucleotide  ·  Universal energy carrier  ·  Phosphate donor  |  Formula: C₁₀H₁₆N₅O₁₃P₃  |  PubChem CID: 5957  |  HMDB: HMDB0000538

ATP is the molecular battery of life. Every cell in every tissue regenerates ATP from ADP and inorganic phosphate using the energy of catabolism, with the cardiomyocyte sitting at the extreme end of demand: the heart turns over its entire ATP pool every 10 seconds at rest. Myosin ATPase consumes ~65%, SERCA2a ~25%, and Na⁺/K⁺-ATPase ~5% of cardiac ATP. ATP depletion during myocardial ischemia impairs SERCA2a within seconds, elevating diastolic Ca²⁺, causing diastolic dysfunction, then contractile failure, arrhythmia, and cell death. Beyond energy transfer, ATP is the phosphate donor for all ~500 human protein kinases, the substrate for cAMP synthesis, and an extracellular danger signal (DAMP) acting through purinergic P2X/P2Y receptors.

adenosine triphosphate adenosine 5′-triphosphate Mg-ATP²⁻ (physiological form)

Overview

Adenosine triphosphate was first characterised as the central carrier of metabolic energy by Fritz Lipmann in 1941, who coined the concept of “high-energy phosphate bonds” to explain how exergonic catabolic reactions are coupled to endergonic work. This framework — that ATP links energy-releasing and energy-consuming reactions — remains the unifying principle of bioenergetics. A resting adult synthesizes and hydrolyzes approximately 40 kg of ATP per day, with most molecules recycled within seconds. In skeletal muscle during maximal exercise, ATP turnover increases 100-fold; neurons consume roughly 20% of whole-body oxygen despite representing only 2% of body mass, almost entirely for Na⁺/K⁺-ATPase to maintain ionic gradients after each action potential.

Beyond energy transfer, ATP acts as a universal phosphate donor for protein kinases — virtually every signal transduction cascade uses ATP hydrolysis to phosphorylate substrates and propagate the signal. ATP is also the substrate for adenylyl cyclase (generating cAMP, the second messenger of catecholamines and glucagon), for RNA polymerases, and for purinergic signaling receptors on cell surfaces. Extracellular ATP released from damaged or activated cells acts as a potent danger-associated molecular pattern (DAMP) that activates P2X ionotropic ion channels (particularly P2X7, driving NLRP3 inflammasome) and P2Y metabotropic receptors (coupled to G-proteins).

In the heart and brain — the tissues with the highest energy demand and least tolerance for ATP depletion — understanding ATP metabolism is inseparable from understanding ischemic injury, heart failure, and neurodegeneration. The creatine phosphate (phosphocreatine) buffer system in cardiomyocytes and neurons exists precisely to regenerate ATP on a subsecond timescale during demand surges that outpace mitochondrial synthesis: creatine kinase transfers the phosphoryl group from phosphocreatine to ADP in milliseconds, providing a 5–10× stoichiometric ATP buffer.

Structure

Structural FeatureDetail
Molecular formulaC₁₀H₁₆N₅O₁₃P₃ (free acid); dianion at physiological pH
Molecular weight507.18 Da
Adenine basePurine; N1, N3, N7, N9 ring nitrogens engage kinase active sites via hydrogen bonds; exocyclic amino N6 at C6; N9 links to ribose via N-glycosidic bond
Ribose sugar5-carbon ribose in C3′-endo conformation; 5′-OH linked to α-phosphate via phosphoester bond; 2′-OH distinguishes ATP from dATP
Triphosphate chainα–β–γ arrangement; β–γ bond has highest free energy of hydrolysis; α–β hydrolysis releases pyrophosphate (PPᴵ) — hydrolyzed by ubiquitous inorganic pyrophosphatases making many biosynthetic reactions irreversible
Mg²⁺ chelationATP functions biologically as Mg-ATP²⁻; Mg²⁺ bridges β and γ phosphates, reducing charge repulsion and presenting correct geometry to kinase and ATPase active sites
Hydrolysis ΔG−30.5 kJ/mol (standard); −45–65 kJ/mol under cellular conditions (lower ADP/ATP ratio, physiological Mg²⁺, temperature)

Mechanism of Action — F₀F₁-ATP Synthase and Cellular ATP Economy

  MITOCHONDRIAL INNER MEMBRANE (proton-motive force ≈ −220 mV)
       │
       │  Electrons from NADH→Complex I, FADH₂→Complex II
       │  flow through ETC: Complex I → CoQ → Complex III → Cyt c → Complex IV
       │  Protons pumped out at Complexes I, III, IV
       ▼
  Proton electrochemical gradient (ΔΨ + ΔpH) established
       │
       │  Protons re-enter via F₀ c-ring (8 c-subunits in human ATP synthase)
       │  ~3 H⁺ per ATP synthesized
       ▼
  F₀ c-ring rotation drives γ-stalk rotation within F₁ α₃β₃ hexamer
       │
       │  Boyer's binding-change mechanism:
       │  Each 120° rotation cycles one β-subunit through:
       │    Open (O) — empty, releases ATP
       │    Loose (L) — binds ADP + Pᵢ loosely
       │    Tight (T) — catalyzes ATP synthesis spontaneously
       ▼
  ATP released into matrix → exported via ANT (adenine nucleotide translocase)
  in exchange for cytosolic ADP

  ATP SYNTHESIS YIELD (aerobic glucose oxidation, ~32 ATP total):
  ─────────────────────────────────────────────────────────────
  Glycolysis (cytoplasm):           2 net ATP + 2 NADH + 2 pyruvate
  Pyruvate dehydrogenase:           2 NADH
  Krebs cycle (×2):                 2 GTP→ATP + 6 NADH + 2 FADH₂
  Oxidative phosphorylation (ETC):  ~25–28 ATP (NADH ≈ 2.5 ATP; FADH₂ ≈ 1.5 ATP)
  ─────────────────────────────────────────────────────────────
  Total:                            ~30–32 ATP per glucose

  CARDIAC ATP CONSUMERS (per beat):
  ─────────────────────────────────────────────────────────────
  Myosin ATPase (actomyosin cross-bridge):  ~65%  — 1 ATP per cycle
  SERCA2a (SR Ca²⁺-ATPase):                ~25%  — 1 ATP per 2 Ca²⁺ pumped
  Na⁺/K⁺-ATPase:                            ~5%  — 1 ATP per 3 Na⁺/2 K⁺
  Other (dynein, kinesin, synthesis):        ~5%
  • Glycolysis: Cytoplasmic 10-enzyme pathway; produces 2 net ATP + 2 NADH + 2 pyruvate per glucose; the only ATP source in anaerobic conditions; rate-limited by phosphofructokinase-1 (PFK-1), allosterically inhibited by high ATP and activated by AMP.
  • Krebs / TCA cycle: Oxidizes 2 acetyl-CoA per glucose through 8 reactions; generates 6 NADH + 2 FADH₂ + 2 GTP; regenerates oxaloacetate; CO₂ released.
  • Electron transport chain: NADH donates electrons at complex I; FADH₂ at complex II; electrons flow to O₂ at complex IV (cytochrome c oxidase), reducing it to H₂O; protons pumped at complexes I, III, IV establishing pmf.
  • F₀F₁-ATP synthase (complex V): Proton flow through the F₀ c-ring rotates the γ-stalk; Boyer’s binding-change mechanism in F₁ makes ATP synthesis thermodynamically spontaneous at the tight site; ~25–28 of ~32 ATP per glucose made here.
  • Creatine phosphate shuttle: Rapid-burst ATP replenishment in cardiomyocytes and neurons; mitochondrial creatine kinase phosphorylates creatine using mitochondrial ATP; cytosolic creatine kinase re-phosphorylates ADP at sites of consumption; PCr/ATP ratio is a sensitive marker of cardiac energetic stress in heart failure (normal ~1.8; HF ~1.0).
  • AMPK energy sensing: AMP-activated protein kinase (activated when AMP rises as ATP falls) is the master catabolic switch: inhibits fatty acid synthesis, mTORC1, and gluconeogenesis; activates fatty acid oxidation, GLUT4 translocation, and mitochondrial biogenesis via PGC-1α.

Physiological Roles

Tissue / Cell TypeRoleEffect
CardiomyocyteMyosin ATPase (contraction), SERCA2a (Ca²⁺ reuptake), Na⁺/K⁺-ATPase (membrane potential)ATP pool recycled every ~10 s at rest; PCr buffer extends capacity ~10×; energetic failure is the first event in ischemic cascade
Skeletal muscleActomyosin cross-bridge cycling during contraction1 ATP per cross-bridge cycle; PCr buffer provides burst capacity (≤10 s); glycolysis sustains anaerobic effort; mitochondrial OxPhos for sustained aerobic work
NeuronNa⁺/K⁺-ATPase (~70% neural energy), synaptic vesicle cycling, axonal transportRepolarisation after each action potential; ~2×10⁷ Na⁺ enter per AP; ~2.5 million Na⁺/K⁺-ATPase pumps per neuron; brain consumes 20% of body O₂ at 2% of body mass
Kidney (proximal tubule)Na⁺/K⁺-ATPase driving secondary active reabsorptionReabsorption of glucose, amino acids, phosphate, bicarbonate; entirely ATP-dependent; most energy-consuming nephron segment; acute tubular necrosis in ischemia reflects ATP depletion
LiverGluconeogenesis, urea cycle, bile synthesis, VLDL/albumin secretion3 ATP per glucose synthesized via gluconeogenesis; 4 ATP per urea molecule; hepatic energy demand rises in fasting and stress states; steatosis impairs mitochondrial ATP production
All cellsProtein kinase substrate (~500 human kinases), DNA/RNA synthesis, chaperone ATPase cyclesSignal transduction, transcription, protein folding — all ATP-dependent; cellular ATP concentration (~5 mM) is maintained within a narrow range; AMP/ATP ratio is the metabolic sensor

Pathology

DiseaseMechanismDrug TargetExample Drug
Myocardial ischemia / MI Coronary occlusion → O₂ deprivation → ETC failure → ATP depleted in seconds → SERCA2a impaired → diastolic Ca²⁺ overload → contractile failure; at <40% normal ATP: K𝐘𝐌P channels open → arrhythmia; mPTP opening → necrosis K𝐘𝐌P channels; Ca²⁺ handling; reperfusion injury (mPTP) Reperfusion (PCI/thrombolysis — restores ATP synthesis); nicorandil (K𝐘𝐌P opener, cardioprotective); SGLT2 inhibitors improve cardiac energetics; investigational mPTP inhibitors
Heart failure Chronic energetic impairment: PCr/ATP ratio falls from ~1.8 to ~1.0; SERCA2a expression/activity reduced 30–50%; diastolic Ca²⁺ overload; mitochondrial dysfunction and ROS production SERCA2a; mitochondrial biogenesis; substrate utilization SERCA2a gene therapy (AAV1-SERCA2a); SGLT2 inhibitors (dapagliflozin, empagliflozin) reduce cardiac oxygen demand; beta-blockers reduce myocardial O₂ consumption
Mitochondrial disease Mutations in mtDNA or nuclear-encoded ETC subunits → impaired ATP synthesis in high-demand tissues (muscle, brain, heart); common mtDNA mutations: m.3243A>G (MELAS), m.8344A>G (MERRF) Complex I–V subunits; mtDNA replication No curative therapy; CoQ10 for some Complex I disorders; riboflavin for Complex I/II deficiency; gene therapy investigational; exercise training increases mitochondrial biogenesis
T2DM / metabolic syndrome Mitochondrial dysfunction + lipid overload reduce ATP synthesis efficiency in skeletal muscle; impaired AMPK activation; reduced glucose oxidation; hepatic ATP depletion contributes to NASH AMPK; mitochondrial biogenesis (PGC-1α); fatty acid oxidation Metformin (activates AMPK via complex I inhibition); exercise training (increases mitochondrial density via PGC-1α); SGLT2 inhibitors promote ketone-based ATP generation in heart

Ischemic cascade — from occlusion to infarction, step by step: (1) Coronary occlusion; (2) Within seconds: ETC fails, ATP falls; (3) 30–60 s: SERCA2a impaired → diastolic Ca²⁺ rises → diastolic dysfunction; (4) 1–2 min: contractile failure, ECG ST changes; (5) 5–10 min: reversible injury transitions to irreversible if ATP <40% normal; (6) K𝐘𝐌P channels open → ventricular arrhythmia risk; (7) 20–40 min: mitochondrial permeability transition pore (mPTP) opens → cytochrome c release → necrosis. Reperfusion before step 5 salvages myocardium. Time-to-balloon target: ≤90 min from first medical contact — each 30-min delay increases 1-year mortality by ~8%.

Connections

Expressed by Cardiomyocyte (highest ATP demand) Modulates SERCA2a (Ca²⁺ pump substrate) Modulated by Proton (pmf drives F₀F₁ synthase) Contains Nitrogen (adenine ring, 5 atoms) Modulated by Magnesium (Mg-ATP chelation) Composed of Phosphorus (triphosphate chain)

References